AstraZeneca PLC - American Depositary Shares (AZN)

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing significant survival benefits.

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.

The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.

Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the ATTR-CM market in the next 3 years.

BridgeBio's acoramidis wins Japan's approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca's Alexion to market it.

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line EGFR-mutated NSCLC over osimertinib.

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Technology and healthcare have both tried for a breakout and failed, courtesy of massive economic forces rocking the boat.

AstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug.

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for small cell lung cancer treatment.

AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion deal includes an initial payment of $425 million, with additional contingent consideration.

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.

The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.

Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.

It’s what they call a “low dollar market” in that general conditions aren’t easy and there aren’t many slam dunk no-brainer setups.

A fundamental analysis of (NASDAQ:AZN): This article explores why quality investors may have a look at ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)

AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong trend in overall survival.

Nvidia's CEO threw cold water on quantum computing by scoffing at its near-term utility. Quantum execs are sharpening their arguments.

Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.